The U.S. Food and Drug Administration is now providing real-time, daily publication updates on adverse event data from its reporting system. In an effort to modernize and provide transparency on ...
A new commission will investigate the prevalence of SSRI antidepressants as adverse event reports document hundreds of cases of homicidal ideation and homicide. A newly released analysis of FDA ...
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have revolutionized the management of metabolic diseases, offering substantial benefits in glycemic control, weight reduction, cardiovascular ...
As Department of Health and Human Services (HHS) and FDA leadership continue to look for ways to boost transparency and reshape the U.S' healthcare infrastructure, the U.S. drug regulator has unveiled ...
The FDA announced that adverse event data from the FAERS will now be published daily. HealthDay News — The US Food and Drug Administration is now providing real-time, daily publication updates on ...
Please provide your email address to receive an email when new articles are posted on . The FDA Adverse Event Reporting System will now host daily publications, instead of quarterly. The agency’s goal ...
Hosted on MSN
FDA starts daily publication of adverse event data
The U.S. Food and Drug Administration said that it has begun the daily publication of adverse event reports related to drugs and biological products. This marks a shift from the previous quarterly ...
Using real-world data from over 300,000 cases, scientists uncovered a significant link between semaglutide and reported vision problems—raising new concerns about the safety profile of this ...
To increase transparency, the agency is publishing data from the FDA Adverse Event Reporting System daily rather than quarterly. (HealthDay News) — The U.S. Food and Drug Administration is now ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback